Health-related quality of life as an endpoint in oncology phase I trials: a systematic review

Frédéric Fiteni 1,2,3*, Isabelle Le Ray 4,5, Ahmad Ousmen 6, Nicolas Isambert 7, Amélie Anota 6,8 and Franck Bonnetain 6,8

Abstract

**Background:** Phase I trials aim to identify the recommended dose for further development. Health-related quality of life (HRQoL) could be a complement to the usual National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale to detect adverse events and define the doses. The objective of this study is to review the phase I in oncology which used HRQoL as endpoint.

**Methods:** A search in PubMed database identified phase I trials in oncology with HRQoL as endpoint, published between January 2012 to May 2016. Hematological and pediatric phase I were excluded.

**Results:** A total of 1333 phase I were identified and 15 trials were identified with HRQoL as endpoint (1.1%). The European Organisation for Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was the most frequently used instrument: 5 studies (33.3%). The targeted dimensions of HRQoL and the minimal clinically important difference were prespecified in 1 study (6.7%) and 2 studies (13.3%), respectively. Twelve studies (80%) described the statistical approach to analyze HRQoL data. Eight studies used the mean change from baseline (60%) to analyse longitudinal HRQoL data, two the mean score at certain times (13.3%), one the linear mixed model for repeated measures (6.7%), one the time to HRQoL score deterioration (6.7%), one percentage of patient-reported symptoms (6.7%). None of the studies used HRQoL to determine the recommended doses.

**Conclusion:** Few phase I studies used HRQoL as endpoint and among studies with HRQoL as endpoint, the methodology of HRQoL measurement and statistical analysis was heterogeneous. HRQoL endpoint not used for assessing the recommended phase II doses.

**Keywords:** Health-related quality of life, Phase I trial, Endpoint, Recommended phase II dose

Background

Phase I trials aim to identify the recommended dose for further development of novel drugs under investigation, or recommended phase II Dose (RP2D). This is a key point for the development of new therapeutic strategies the efficacy and toxicity observed in phase II trials and therefore the development of the agent depends on the accuracy of this dose. The classic paradigm that the optimal RP2D has to be the maximal tolerated dose (MTD) has been challenged within the last years, especially concerning molecularly targeted agent. Opinions diverge also on what type and grades of toxicities should be used to define dose-limiting toxicity (DLT) [1, 2]. The DLT is most of the time determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) targeting grades 3 and 4.

Doses recommended based on current MTD definition could be higher than needed especially for molecularly targeted agents, carrying the risk of unnecessary toxicities [3].

The duration of toxicity and/or the occurrence of late toxicity are not taken into account in the definition of DLT [3]. Moderate toxicities experienced over a long period could impair patients’ HRQoL and are not taken into account in the usual definition of DLT based on the NCI-CTCAE assessed by clinicians [4]. Moreover, the...
accuracy of physicians reporting of chemotherapy adverse events have proven weak sensitivity and specificity when compared to patients reported outcomes (PROs) [5]. Therefore, the usual definition of DLT may not appropriately reflect the patient's feelings regarding the tolerability of the received treatment.

HRQoL and/or PROs could be a complement to the NCI-CTCAE scale to detect adverse events and define the doses.

The objective of this study was to assess the current use of HRQoL as an endpoint (primary or secondary) in phase I oncologic trials. However, its use is most likely not widely spread, as primary or secondary endpoint.

Methods
Search strategy and selection for studies

Eligible trials were phase I trials in oncology with HRQoL as endpoint (primary or secondary). Literature searches in PubMed database (January 2012 to May 2016) were performed. Literature search was performed from 2012 to be representative of the current use of HRQoL in phase I trials. We focused on studies in adults solid tumors. Therefore, haematological and pediatric phase I were excluded.

The following strategies were used: (Neoplasms[MeSH Terms] OR neoplasm*[Title/Abstract] OR cancer*[Title/Abstract]) AND ("clinical trial, phase I"[Publication Type]) OR (trial*[Title/Abstract] AND (phase I*[Title/Abstract] OR phase 1*[Title/Abstract] OR phase one*[Title/Abstract]))

Data extraction

Two authors (F. F., A.O) independently extracted information using predefined data abstraction forms. All data were checked for internal consistency, and disagreements were resolved by discussion among the investigators. The following data were extracted: general items (number of patients, year of publication, study period, number of centers, nationality of the first author, academic, mixed or industrial trial), primary endpoint, design of the study, items related to HRQoL measurement, statistical analysis and reporting (rational for HRQoL assessment, methods of data collection, HRQoL questionnaire, evidence of HRQoL questionnaire validity, method/algorithm for scoring the questionnaire, planned schedule of questionnaires, definition of the minimal clinically important difference (MCID), methods used to analyse longitudinal HRQoL data, etc).

Statistical analysis of HRQoL

The targeted dimensions of HRQoL were prespecified in one study (6.7%). Two studies (13.3%) determined the minimal clinically important difference (MCID). These two studies used the EORTC QLQ-C30 questionnaire, one used a 5-point difference and one 10-point difference in the HRQoL scores as the MCID. Three studies (20%) mentioned the population data set for HRQoL analysis and all of them used a modified intention-to-treat analysis.

The number of HRQoL data at baseline and at subsequent time points, the HRQoL scores at baseline for each group and each dimension, the profile of missing data at baseline, the statistical approaches for dealing with missing data were adequately reported in 3 (20%), 2 (13.3%), 3 (20%) and 1 (6.7%) studies, respectively. The method for dealing with missing data was the pattern mixture method. No study provided the reasons why data were missing. Twelve studies (80%) described the different statistical methods/analyses were: the mean change from baseline for 8 studies (60%), mean score at certain times for two studies (13.3%), linear mixed model for

Analyses were conducted with the use of SAS software, version 9.3 (SAS Institute).

Results

Characteristics of the studies

The characteristics of the studies are described in Table 1. A total of 1333 phase I articles were identified and 15 trials were identified with HRQoL as endpoint (1.1%) (Fig. 1). Among these 15 trials, 14 (93.3%) were academic studies and 1 (6.7%) had a mixed financial support. Twelve studies (80%) enrolled patients with advanced cancers and 3 studies (20%) with localized cancers. The trial concerned targeted therapy (2 trials, 13.3%), chemotherapy (2, 13.3%), immunotherapy (2, 13.3%), radiotherapy associated with a targeted therapy (2, 13.3%), radiotherapy (1, 6.7%), surgery (1, 6.7%), chemoembolization (1, 6.7%) or others (4, 26.6%). Regarding the design, 8 studies (53.3%) used a modified Fibonacci dose escalation based on a 3 + 3 scheme, 2 (13.3%) used a continual reassessment method and 5 (33.3%) other methods. MTD was the most frequent primary endpoint (60%).

HRQoL measurement

HRQoL was not used as primary endpoint in any trials (one ancillary study). Two trials (13.3%) provided no result for HRQoL. The EORTC Quality of Life Questionnaire C30 (QLQ-C30) was the most frequently used instrument (5 studies (33.3%)). The reference of the HRQoL instrument validation was provided in 6 studies (40%). The planned schedule of HRQoL assessment was reported in 10 trials (66.7%) (Table 2).
| First author | Patients | Treatment | Design | Primary endpoint | Secondary endpoint |
|-------------|----------|-----------|--------|------------------|-------------------|
| Ringash [8] | Locally advanced head and neck cancer | Radiotherapy | Fleming multi-step algorithm dose escalation | Incidence of radiation-induced acute grade 4 toxicity | |
| Crew [14]   | Localized breast cancer | Polyphenon E | Time-to-event continual reassessment method | MTD | Dose-related biologic effects, HRQoL |
| Xiao [15]   | Advanced hepatocellular carcinoma | Tyroserleutide | 3 + 3 dose escalation design | MTD, 6-month OS, response, HRQoL | |
| Lin [16]    | Advanced breast cancer | Molecular targeted therapy + radiotherapy | 3 + 3 dose escalation design | MTD | ORR, non CNS ORR, PFS, OS, site of first progression, progression free at 6 months, cause of deaths, HRQoL |
| Kanai [17]  | Advanced pancreatic and biliary tract cancer | Curcumin | Rolling 6 | MTD, safety, pharmacokinetic, response rate, HRQoL | |
| Tsubata [9] | Advanced non-small cell lung cancer | Chemotherapy | Not clear | MTD | HRQoL, pharmacokinetic |
| Han [18]    | Localized colorectal cancer | Calcium-magnesium | Randomized, double-blind, placebo controlled | Pharmacokinetic | EMG, patient-reported neurotoxicity symptoms, study treatment preference for reducing neurotoxicity |
| Rouanne [19]| Advanced cancers | Molecular targeted therapy | NA | HRQoL (ancillary study) | |
| Stephenson [20]| Advanced cancers | Ascorbic acid | 3 + 3 dose escalation design | MTD, pharmacokinetic, HRQoL | |
| Hunn [21]   | Glioblastoma | Vaccine | Single cohort | Feasibility, safety | Response rate, 6 month PFS, rate of vaccine-induced immune response, HRQoL |
| Reiss [22]  | Advanced cancer with peritoneal carcinomatosis | Molecular targeted therapy + radiotherapy | 3 + 3 dose escalation design | Safety | Response rate, HRQoL |
| Cusi [23]   | Advanced cancers | Vaccine | 3 + 3 dose escalation design | MTD, most effective biological dose | Response, PFS, OS, HRQoL |
| McRee [24]  | Advanced cancers | Molecular targeted therapy | 3 + 3 dose escalation design | MTD | Safety, response, HRQoL |
| Chin [25]   | Localized prostate cancer | Surgery | Single cohort | Safety, feasibility | Response, HRQoL |
| Anota [11]  | Advanced hepatocellular carcinoma | Chemoembolisation | Continual reassessment method | MTD | HRQoL |

HRQoL: Health-related quality of life, MTD: maximum tolerated dose, OS: overall survival, PFS: progression free survival, ORR: overall response rate, CNS: central nervous system.
repeated measures (LMM) (one study, 6.7%), time to HRQoL score deterioration (TTD) (1 study, 6.7%), percentage of patient-reported symptoms (1, 6.7%). None of the studies identified the RP2D using HRQoL measurement (Table 2).

Discussion
To our knowledge, this is the first systematic review related to the use of HRQoL in phase I oncology trials. We demonstrated that few phase I studies used HRQoL as endpoint showing that HRQoL is not yet considered of major interest in phase I trials. Moreover, among studies with HRQoL as endpoint, none identified the RP2D according to the HRQoL results and the methodology of HRQoL measurement and statistical analysis was heterogeneous.

The MTD is determined by DLT which is usually defined as any grade 3–4 non-haematological or grade 4 haematological toxicity occurring during the first cycle of treatment. Nevertheless, Paoletti et al., in an international survey implying 65 experts, showed that these experts are willing to consider some grade 2 toxicities as DLT and that the notion of evolution of the symptoms should be regarded as important while it is poorly assessed in current practice [6]. These moderate toxicities are not taken into account in the usual definition of DLT based on the NCI-CTCAE assessed by clinicians at cycle 1. Therefore, the usual definition of DLT may not appropriately reflect the patient’s feelings regarding the tolerability of the treatment received. Some moderate grade 2 adverse events may have an impact on quality of life and in consequence on compliance of the treatment.

Moreover, 50% of the grade 3/4 toxicities of molecular targeted therapies seem to occur after cycle 1. Postel-Vinay et al. presented data showing that, among a large number of patients participating in molecular targeted therapies phase I trials, response rate is not confined to patients treated at doses close to the MTD [3].

Furthermore, Henon and all showed in a survey including 52 patients enrolled in 27 phase I trials that the patients’ most feared AEs are gastrointestinal toxicities,
| First author | HRQoL questionnaire | Timing of assessment | Targeted dimensions | MCID | Statistical approach for HRQoL analysis | QoL data interpretation |
|--------------|---------------------|---------------------|-------------------|------|----------------------------------------|------------------------|
| Ringash [8]  | FACT-HN             | Baseline, 6 and 12 months after completion of radiotherapy |                  | Mean change at 6 months, mean change at 12 months, linear mixed model for repeated measure | Better through time in all groups and no relationship with dose level of radiation |
| Crew [14]    | SF-36               | Baseline and 6 months |                  | Mean change from baseline | Finally, no significant change in quality of life as assessed by the SF-36 was observed in either treatment group |
| Xiao [15]    |                    |                      |                  | Mean change from baseline | Not reported |
| Lin [16]     | FACT-B              | Baseline, 6 and 12 months |                  | Mean change from baseline | No comparison between the different tested doses (data missing because of death or withdrawal. « Quality of life according to the FACT-Bi was generally worse at 6 months for women on study. However, the interpretations of these data are limited by the small number of women with results at both time points and because over half of patients had progressed by that time. » |
| Kanai [17]   | QLQ-C30             | Each cycle           |                  | Baseline vs best score during treatment intake | No comparison between the dose groups. « Since improved QOL has been demonstrated to contribute to a better outcome in cancer patients it is tempting to speculate that Theracurmin® can improve the outcome of cancer patients through an improvement in QOL. » |
| Tsubata [9]  | FACT-L              | Every 4 weeks until 12 weeks after the start of treatment |                  | Mean score at 12 weeks | No differences observed between the treatment doses. « The overall response rate was 1/8, toxicity was acceptable and the QOL score was good. This regimen is therefore suitable for use in elderly patients with NSCLC in an outpatient setting. » |
| Han [18]     | After treatment cycles 1 and 2 |                  |                  | Percentage | No treatment effect. « Significantly fewer patients preferred Ca/Mg infusions for reducing their neurotoxicity symptoms than those who preferred placebo or neither treatment (26% versus 74%; P = 0.01). » |
| Rouanne [19] | SF-12, BDI-SF, FSFI, IIEF | Baseline, 1 month |                  | Mean change from baseline | « The patients scored statistically significant decrease in physical health component on the SF-12 after 1-month treatment whereas mental component scale scores did not differ significantly. » |
| Stephenson [20] | QLQ-C30          | Baseline and prior each infusion of vitamin C |                  | Mean score at each cycle | Not used in the discussion. |
| Hunn [21]    | QLQ-C30             |                      |                  |          | Not used in the discussion. |
| Reiss [22]   | QLQ-C30             | Baseline and every 2 cycles |                  | 10 points Mean change from baseline | Extensive interpretation. « Our regimen was well tolerated by measures of toxicity and by our QoL data. » « Those who discontinued therapy early, either due to progression of disease, adverse effects, or a global inability to tolerate further treatment, may have had inferior QoL while on this regimen as compared with those who were able to continue the regimen. » |
| First author | HRQoL questionnaire | Timing of assessment | Targeted dimensions | MCID | Statistical approach for HRQoL analysis | QoL data interpretation |
|--------------|---------------------|----------------------|---------------------|------|----------------------------------------|------------------------|
| Cusi [23]    | Mean change from baseline | Not used in the discussion. |
| McRee [24]   | PHQ-9, GAD-7         | Not reported |
| Chin [25]    | IPSS, IIEF-15, UCLA-PCI-SF | Mean change from baseline | « Functional outcomes, IPSS and IIEF-15, both showed a favorable anticipated trend of initial deterioration with subsequent gradual improvement toward baseline levels. » |
| Anota [11]   | QLQ-C30 Baseline and at days 15, 30 and 60 after chemoembolisation | Global health status, physical functioning, fatigue and pain | 5 points | Time to deterioration | Overall, patients included at the 10 mg idarubicin dose level seemed to have a longer TTD of HRQoL than patients included at the 5 mg or 15 mg idarubicin dose levels. HRQoL results are thus consistent with the 10 mg idarubicin dose level selected as the MTD |

FACT-HN Functional Assessment of Cancer Therapy Head and neck, SF-36 Short form of the medical outcomes study, FACT-B Functional Assessment of Cancer Therapy Breast, QLQ-C30 European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire, FACT-L Functional Assessment of Cancer Therapy Lung, SF-12 Short Form-12 Health, BDI-SF Beck Depression Inventory Short Form, FSFI Female Sexual Function Index, IIEF International Index of Erectile Function, PHQ-9 Patient Health Questionnaire, GAD-7 Generalized Anxiety Disorder 7-item, IPSS International Prostate Symptom Score, UCLA-PCI-SF Bowel habits domain of University of California, Los Angeles Prostate Cancer Index-Short form.
neurological toxicities and personality change, which differs from the physicians’ most feared toxicities [7]. We also know that there may be discrepancies between patients and physicians reporting toxicities.

In that context, HRQoL and patient-reported outcomes may be an added value as a complement to the usual NCI-CTCAE scale to detect toxicities and define the RP2D. Nevertheless, this review shows that HRQoL has been poorly investigated in oncology phase I clinical trials. None of the studies included in our review used HRQoL as primary endpoint or identified the RP2D using HRQoL measurements. Three studies analyzed HRQoL according to the dose levels. In the Ringash et al. [8] and Tsubata et al. [9] studies there was no relationship between dose level and HRQoL while they observed increased toxicities according to the dose of treatment. In Anota et al. study, patients presented a longer TTD at the MTD (10 mg idarubicin) than at the lower level (5 mg idarubicin) for global health status, physical functioning, fatigue and pain dimensions. These results consolidate the selection of the RP2D.

In the perspective of enabling patients to speak on themselves, without the filter of physicians, a patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) was developed by the National Cancer Institute [10]. These PRO-CTCAEs could be a complement of the NCI-CTCAEs to define the DLT or we could use the PRO-CTCAEs scale rather than the NCI-CTCAEs scale to determine the RP2D in a more patient-oriented perspective. Nevertheless, some moderate adverse events which could have an impact on patients’ HRQoL over time might not be taken into account by the PRO-CTCAE. Further researches are mandatory and the first step could be to implement PRO-CTCAEs as secondary endpoint in order to compare the results obtained with the NCI-CTCAEs.

HRQoL questionnaires could bring an added value in phase I as a complement to results obtained on toxicity, as the study of Anota et al. [11] to see if there’s no impact on HRQoL at the MTD compared to lower doses. A longitudinal analysis of HRQoL could be an alternative way to assess the impact of the MTD in a clinically meaningful way. The two main methods for longitudinal analysis of HRQOL data in oncology are to be considered: the linear mixed model for repeated measures or the time to HRQoL score deterioration [12]. Nevertheless, no guidelines exist for the MCID definition and the longitudinal analysis of HRQoL. The optimal definition of MCID should be explored according to cancer localization, treatment, and setting with and evidence-based approach and guidelines. Ongoing SISA-QOL and qRECIST phase III projects, supported by the EORTC, are warranted for longitudinal HRQOL [13]. Once these guidelines for phase III trials will be published, methodological researches will be mandatory to analyze their potential implementation in phase I trials.

The main limitation of our study is the short number of studies with HRQoL as endpoints. None of them identified the RP2D with HRQoL as endpoint. Therefore, we are unable to provide any example of a drug that is used in the daily life and which dose has been determined by HRQoL or PROs in phase I. Moreover, the side-effects of the drugs are frequently not known as many drugs assessed in phase I are first-in-human and can be first-in-kind. Therefore, the choice of a HRQoL instruments can be difficult in this context.

Conclusion
HRQoL could be an added value for the assessment of the RP2D and further methodological research is necessary to implement HRQoL in oncology phase I trials.

Acknowledgements Not applicable.

Abbreviations
DLT: Dose-limiting toxicity; EORTC QLQ-C30: European Organisation for Treatment of Cancer Quality of Life Questionnaire C30; HRQoL: Health-related quality of life; MCID: Minimal clinically important difference; MTD: Maximal tolerated dose; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; PRO-CTCAE: Patient-reported outcomes version of the common terminology criteria for adverse events; PROs: Patients reported outcomes; RP2D: Recommended phase II Dose; TTD: Time to HRQoL score deterioration

Funding
No funding.

Availability of data and materials
The dataset(s) supporting the conclusions of this article is (are) included within the article (and its additional file(s)).

Authors’ contributions
FF: conception/design, collection, data analysis and interpretation, manuscript writing, final approval manuscript. FR: Conception/Design, Manuscript writing, final approval manuscript. AO: collection, data analysis and interpretation, manuscript writing, final approval manuscript. NL: Conception/Design, Manuscript writing, final approval manuscript. AA: Conception/Design, Manuscript writing, final approval manuscript. FB: Conception/Design, Manuscript writing, final approval manuscript. All authors have read and approved the manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medical Oncology, University Hospital of Nîmes, Rue du Pr Henri Pujol, 30029 Nîmes Cedex 9, France. 2Institut de Recherche en
Cancéropôle de Montpellier (IRCM), INSERM U1194, Montpellier, France.
1. University of Montpellier, Montpellier, France. 2. Department of Neuroradiology, Strasbourg University Hospital, Strasbourg, France. 3. Department of Medical Epidemiology and Biostatistics, Karolinska University, Stockholm, Sweden. 4. Methodology and Quality of Life in Oncology Unit, INSERM UMR 1098, University Hospital of Besançon, Besançon, France. 5. Medical Oncology Department, Centre GF Leclercq, Dijon, France. 6. French National Platform Quality of Life and Cancer, Dijon, France.

Received: 4 October 2017 Accepted: 4 April 2019 Published online: 16 April 2019

References
1. Haines IE. Dose selection in phase I studies: why we should always go for the Most effective. J Clin Oncol. 2008;26(1):3650–2.
2. Steijger S, Wiemer E. Dose selection in phase I studies: why we should always go for the top. J Clin Oncol. 2008;26(10):1576–8.
3. Postel-Vinay S, Gomez-Roca C, Mollé LR, Anota A, Levy A, Judson I, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol. 2011;29(13):1728–35.
4. Verweij J, Disis ML, Cannistra SA. Phase I studies of drug combinations. J Clin Oncol. 2010;28(30):4545–6.
5. Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol. 2004;22(17):3485–90.
6. Paletti R, Le Tourneau C, Verweij J, Stui LL, Seymour L, Postel-Vinay S, et al. Defining dose-limiting toxicities for phase I trials of molecularly targeted agents: results of a DLT-TARGETT international survey. Eur J Cancer. 2014;50(12):2050–6 Available from: https://doi.org/10.1016/j.ejca.2014.04.030.
7. Hencro EF, Liss D, Paletti R, Tisell L, Ce TC, Laney E, et al. Patient-reported tolerability of adverse events in phase I trials. ESMO Open. 2017;2(2):e000148.
8. Rings R, Leckwood G, O’Sullivan B, Warde P, Bayley A, Cummings B, et al. Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/I trial. Radiother Oncol. 2008;87(2):181–7.
9. Tsubata Y, Okimoto T, Muria K, Karino F, Iwamoto S, Tada M, et al. Phase I trial of polyphenon E in women with hormone receptor-negative breast cancer. Anticancer Res. 2013;33(1):261–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23267154.
10. Basch E, Reeve BB, Mitchell SA, Causier SM, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JNCI J Natl Cancer Inst. 2014;106(9):dju244.
11. Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil J-P, Minello A, et al. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer. 2013;49(2):431–8.
12. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I trial of Velparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal Carcinomatosis. Clin Cancer Res. 2015;21(1):168–76.
13. Cusi MG, Botta C, Pastina P, Rossetti MG, Dreschi E, Guidelli GM, et al. Phase I trial of trilumetidine synthase poly-epi-protein (TP3P) vaccine in advanced cancer patients. Cancer Immunol Immunother. 2015;64(9):1159–73.
14. McRee AE, Sanoff HK, Carlson C, Ivanova A, O’Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BMK120 in patients with advanced refractory solid tumors. Investig New Drugs. 2015;33(6):1225–31.
15. Chin J, Billia M, Relle J, Roethke MC, Popeneciu M, Kuru TH, et al. Magnetic resonance imaging–guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase I clinical trial. Eur Urol. 2016;70(3):447–55.

BMC Cancer (2019) 19:361
Page 8 of 8

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions